CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 target
Drug / intervention
Abacavir sulfate +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000872
NCT00000872Phase 2Completed
CompareCT.gov

Early Intensive Antiretroviral Combination Therapy in HIV-1 Infected Infants and Children

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 4, 2021

In Brief

A Phase 2 clinical trial evaluating Abacavir sulfate, Nelfinavir mesylate, and 4 other interventions for HIV Infections. Completed, enrolled 55 participants across 12 sites.

Detailed Summary

This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions. Various anti-HIV drug combinations need to be tested in order to find the best way to treat infants and children who have been infected with HIV during birth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Study CompletionJan 1, 2005
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Abacavir sulfatedrug

Nelfinavir mesylatedrug

Nevirapinedrug

Lamivudinedrug

Stavudinedrug

Zidovudinedrug